A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Clinical trial NCT06356311 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06356311
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-03
- Primary completion
- 2027-01-04
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.